40 related articles for article (PubMed ID: 8584980)
1. Exploring the nigrostriatal and digestive interplays in Parkinson's disease using dynamic total-body [
Xin M; Wang Y; Yang X; Li L; Wang C; Gu Y; Zhang C; Huang G; Zhou Y; Liu J
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2271-2282. PubMed ID: 38393375
[TBL] [Abstract][Full Text] [Related]
2. Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study.
Wilson H; Dervenoulas G; Pagano G; Tyacke RJ; Polychronis S; Myers J; Gunn RN; Rabiner EA; Nutt D; Politis M
Brain; 2019 Oct; 142(10):3116-3128. PubMed ID: 31504212
[TBL] [Abstract][Full Text] [Related]
3.
Sun X; Tan X; Zhang Q; He S; Wang S; Zhou Y; Huang Q; Jiang L
EJNMMI Phys; 2024 Apr; 11(1):40. PubMed ID: 38662044
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum: Characteristics and influencing factors of
Kangli F; Hongguang Z; Yinghua L; Xiaoxiao D; Yuyin D; Lulu G; Yi L; Zhihui S; Ying Z
Front Neurol; 2023; 14():1289550. PubMed ID: 37808508
[TBL] [Abstract][Full Text] [Related]
5. Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson's Disease.
Niu J; Zhong Y; Jin C; Cen P; Wang J; Cui C; Xue L; Cui X; Tian M; Zhang H
Neurosci Bull; 2024 Jun; 40(6):743-758. PubMed ID: 38483697
[TBL] [Abstract][Full Text] [Related]
6. Data-driven identification of diagnostically useful extrastriatal signal in dopamine transporter SPECT using explainable AI.
Nazari M; Kluge A; Apostolova I; Klutmann S; Kimiaei S; Schroeder M; Buchert R
Sci Rep; 2021 Nov; 11(1):22932. PubMed ID: 34824352
[TBL] [Abstract][Full Text] [Related]
7. Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings.
Hou H; Wang C; Jia S; Hu S; Tian M
Neurosci Bull; 2014 Oct; 30(5):765-76. PubMed ID: 25260796
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography in the differential diagnosis of parkinsonism.
Rinne JO
J Mov Disord; 2009 Oct; 2(2):53-7. PubMed ID: 24868357
[TBL] [Abstract][Full Text] [Related]
9. Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans.
Nye JA; Votaw JR; Bremner JD; Davis MR; Voll RJ; Camp VM; Goodman MM
Nucl Med Biol; 2014 Mar; 41(3):217-22. PubMed ID: 24533985
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.
Shen LH; Liao MH; Tseng YC
J Biomed Biotechnol; 2012; 2012():259349. PubMed ID: 22570524
[TBL] [Abstract][Full Text] [Related]
11. PET radiotracers: crossing the blood-brain barrier and surviving metabolism.
Pike VW
Trends Pharmacol Sci; 2009 Aug; 30(8):431-40. PubMed ID: 19616318
[TBL] [Abstract][Full Text] [Related]
12. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs.
Booij J; Kemp P
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):424-38. PubMed ID: 17968545
[TBL] [Abstract][Full Text] [Related]
13. Imaging the addicted human brain.
Fowler JS; Volkow ND; Kassed CA; Chang L
Sci Pract Perspect; 2007 Apr; 3(2):4-16. PubMed ID: 17514067
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
[TBL] [Abstract][Full Text] [Related]
15. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
[TBL] [Abstract][Full Text] [Related]
16. PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease.
Rinne JO; Laihinen A; Någren K; Ruottinen H; Ruotsalainen U; Rinne UK
Synapse; 1995 Oct; 21(2):97-103. PubMed ID: 8584980
[TBL] [Abstract][Full Text] [Related]
17. PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease.
Laihinen AO; Rinne JO; Någren KA; Lehikoinen PK; Oikonen VJ; Ruotsalainen UH; Ruottinen HM; Rinne UK
J Nucl Med; 1995 Jul; 36(7):1263-7. PubMed ID: 7790953
[TBL] [Abstract][Full Text] [Related]
18. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
19. PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain.
Farde L; Halldin C; Müller L; Suhara T; Karlsson P; Hall H
Synapse; 1994 Feb; 16(2):93-103. PubMed ID: 8197578
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
